| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Felipe D Pacheco, Mauricio L DA Silva, Graziela Batista, Witória Santos, Adalberto A DE Castro, Lara Canever, Alexandra I Zugn. Olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. Anais da Academia Brasileira de Ciencias. vol 90. issue 2. 2018-07-06. PMID:29898114. |
olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. |
2018-07-06 |
2023-08-13 |
rat |
| Felipe D Pacheco, Mauricio L DA Silva, Graziela Batista, Witória Santos, Adalberto A DE Castro, Lara Canever, Alexandra I Zugn. Olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. Anais da Academia Brasileira de Ciencias. vol 90. issue 2. 2018-07-06. PMID:29898114. |
then, we tested clozapine withdrawal in association with two widely used schizophrenia models: neonatal immune challenge by polycitidilic-polyinosinic acid (polyi:c) and ketamine. |
2018-07-06 |
2023-08-13 |
rat |
| Felipe D Pacheco, Mauricio L DA Silva, Graziela Batista, Witória Santos, Adalberto A DE Castro, Lara Canever, Alexandra I Zugn. Olfactory deficit as a result of clozapine withdrawal syndrome in an animal model of schizophrenia: preliminary results. Anais da Academia Brasileira de Ciencias. vol 90. issue 2. 2018-07-06. PMID:29898114. |
it was produced, for the first time, an olfactory deficit induced by clozapine withdrawal in wistar rats subjected to schizophrenia animal models. |
2018-07-06 |
2023-08-13 |
rat |
| Seunghyun Jeon, Se Hyun Kim, Soon Young Shin, Young Han Le. Clozapine reduces Toll-like receptor 4/NF-κB-mediated inflammatory responses through inhibition of calcium/calmodulin-dependent Akt activation in microglia. Progress in neuro-psychopharmacology & biological psychiatry. vol 81. 2018-07-03. PMID:28431901. |
clozapine is an atypical antipsychotic agent used in the treatment of schizophrenia and severe mood disorders. |
2018-07-03 |
2023-08-13 |
Not clear |
| b' Dragana Ignjatovi\\xc4\\x87 Risti\\xc4\\x87, Dan Cohen, Andrea Obradovi\\xc4\\x87, Katarina Niki\\xc4\\x87-\\xc4\\x90uri\\xc4\\x8di\\xc4\\x87, Marija Dra\\xc5\\xa1kovi\\xc4\\x87, Darko Hini\\xc4\\x8. The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. Nordic journal of psychiatry. vol 72. issue 2. 2018-06-27. PMID:29125018.' |
the glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. |
2018-06-27 |
2023-08-13 |
Not clear |
| Dan Siskind, Victor Siskind, Steve Kisel. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 62. issue 11. 2018-06-26. PMID:28655284. |
clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. |
2018-06-26 |
2023-08-13 |
Not clear |
| Dan Siskind, Victor Siskind, Steve Kisel. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 62. issue 11. 2018-06-26. PMID:28655284. |
clozapine is the most effective antipsychotic for the 25% to 33% of people with schizophrenia who are treatment resistant, but not all people achieve response. |
2018-06-26 |
2023-08-13 |
Not clear |
| Dan Siskind, Victor Siskind, Steve Kisel. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 62. issue 11. 2018-06-26. PMID:28655284. |
a 40% response rate to clozapine suggests that 12% to 20% of people with schizophrenia will be ultra-resistant. |
2018-06-26 |
2023-08-13 |
Not clear |
| J S Kim, C M Park, J A Choi, E Park, H J Tchoe, M Choi, J K Suh, Y H Kim, S H Won, Y C Chung, K Y Bae, S K Lee, S C Park, S H Le. The association between season of birth, age at onset, and clozapine use in schizophrenia. Acta psychiatrica Scandinavica. vol 136. issue 5. 2018-06-05. PMID:28741647. |
the association between season of birth, age at onset, and clozapine use in schizophrenia. |
2018-06-05 |
2023-08-13 |
Not clear |
| J S Kim, C M Park, J A Choi, E Park, H J Tchoe, M Choi, J K Suh, Y H Kim, S H Won, Y C Chung, K Y Bae, S K Lee, S C Park, S H Le. The association between season of birth, age at onset, and clozapine use in schizophrenia. Acta psychiatrica Scandinavica. vol 136. issue 5. 2018-06-05. PMID:28741647. |
this study aimed to determine whether the rate of clozapine use, an indicator of refractoriness in schizophrenia, is associated with the season of birth and age at onset in patients with schizophrenia based on nationwide data. |
2018-06-05 |
2023-08-13 |
Not clear |
| David M Taylo. Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard? CNS drugs. vol 31. issue 3. 2018-06-04. PMID:28258419. |
clozapine for treatment-resistant schizophrenia: still the gold standard? |
2018-06-04 |
2023-08-13 |
Not clear |
| Thomas Re Barnes, Verity C Leeson, Carol Paton, Louise Marston, Linda Davies, William Whittaker, David Osborn, Raj Kumar, Patrick Keown, Rameez Zafar, Khalid Iqbal, Vineet Singh, Pavel Fridrich, Zachary Fitzgerald, Hemant Bagalkote, Peter M Haddad, Mariwan Husni, Tim Amo. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health technology assessment (Winchester, England). vol 21. issue 49. 2018-06-04. PMID:28869006. |
when treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. |
2018-06-04 |
2023-08-13 |
Not clear |
| Lama Souaiby, Claire Gauthier, Christine Rieu, Marie-Odile Krebs, Emmanuelle Advenier-Iakovlev, Raphaël Gaillar. Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study. Schizophrenia research. vol 188. 2018-05-30. PMID:28139358. |
to evaluate efficacy and tolerability of the combination of clozapine with an antipsychotic long-acting injectable (lai) in multi-episode patients with schizophrenia or schizoaffective disorder. |
2018-05-30 |
2023-08-13 |
Not clear |
| Nicholas Myles, Hannah Myles, Scott R Clark, Robert Bird, Dan Siskin. Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations. The Australian and New Zealand journal of psychiatry. vol 51. issue 10. 2018-05-28. PMID:28747065. |
clozapine is the most effective medication for treatment-refractory schizophrenia; however, its use is contraindicated in people who have had previous clozapine-induced neutropenia. |
2018-05-28 |
2023-08-13 |
Not clear |
| Lyang Huh, Bong Ju Le. [Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia]. Turk psikiyatri dergisi = Turkish journal of psychiatry. vol 28. issue 3. 2018-05-25. PMID:28936820. |
clozapine has been used as a treatment option for tdt in patients with schizophrenia. |
2018-05-25 |
2023-08-13 |
Not clear |
| Katalin Tóth, Gábor Csukly, Dávid Sirok, Ales Belic, Ádám Kiss, Edit Háfra, Máté Déri, Ádám Menus, István Bitter, Katalin Monostor. Potential Role of Patients' CYP3A-Status in Clozapine Pharmacokinetics. The international journal of neuropsychopharmacology. vol 20. issue 7. 2018-05-23. PMID:28340122. |
the atypical antipsychotic clozapine is effective in treatment-resistant schizophrenia; however, the success or failure of clozapine therapy is substantially affected by the variables that impact the clozapine blood concentration. |
2018-05-23 |
2023-08-13 |
Not clear |
| Rachel J Suetani, Dan Siskind, Heidi Reichhold, Steve Kisel. Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis. Psychopharmacology. vol 234. issue 20. 2018-05-22. PMID:28879574. |
we undertook a systematic review to examine the evidence for genetic variation being associated with secondary metabolic outcomes in patients with schizophrenia on clozapine, under both longitudinal and cross-sectional study designs. |
2018-05-22 |
2023-08-13 |
Not clear |
| K Sarathy, C Alexopoulo. A successful re-trial after clozapine myopericarditis. The journal of the Royal College of Physicians of Edinburgh. vol 47. issue 2. 2018-05-21. PMID:28675186. |
clozapine is also the most efficacious agent in refractory schizophrenia. |
2018-05-21 |
2023-08-13 |
Not clear |
| Conrad Molins, Mar Carceller-Sindreu, Helena Navarro, Cristina Carmona, Marina Piñeiro, Estrella Martínez, Enric Álvarez, Maria J Portell. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients. Psychiatry research. vol 258. 2018-05-10. PMID:29024893. |
nineteen clinically stable patients with schizophrenia or schizoaffective disorder treated with clozapine monotherapy completed demographic and clinical interviews. |
2018-05-10 |
2023-08-13 |
Not clear |
| Ximena López Hill, Analía Richeri, María Cecilia Scorz. Clozapine blockade of MK-801-induced learning/memory impairment in the mEPM: Role of 5-HT Physiology & behavior. vol 179. 2018-05-01. PMID:28705535. |
clozapine blockade of mk-801-induced learning/memory impairment in the mepm: role of 5-ht cognitive impairment associated with schizophrenia (cias) is highly prevalent and affects the overall functioning of patients. |
2018-05-01 |
2023-08-13 |
Not clear |